Dual TGFβ/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast
Prasad M., Kumar B., Bhat-Nakshatri P., Anjanappa M., Sandusky G., Miller KD.
Animal Study, published in Mol Cancer Res (2019) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Mol Cancer Res (2019)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 30992305
- PMCID
- PMC6610652
- DOI
- 10.1158/1541-7786.mcr-19-0165
- Citations
- 15
Abstract (original English)
Functional modeling of normal breast epithelial hierarchy and stromal-epithelial cell interactions have been difficult due to inability to obtain sufficient stem-progenitor-mature epithelial and stromal cells. Recently reported epithelial reprogramming assay has partially overcome this limitation, but cross-contamination of cells from the feeder layer is a concern. The purpose of this study was to develop a feeder-layer-independent and inexpensive method to propagate multiple cell types from limited tissue resources. Cells obtained after enzymatic digestion of tissues collected at surgery or by core-needle biopsies were plated on tissue culture dishes precoated with laminin-5-rich-conditioned media from the rat bladder tumor cell line 804G and a defined growth media with inhibitors of ROCK, TGFβ, and BMP signaling. Cells were characterized by flow cytometry, mammosphere assay, 3D cultures, and xenograft studies. Cells from the healthy breasts included CD10 + /EpCAM - basal/myoepithelial, CD49f + /EpCAM + luminal progenitor, CD49f - /EpCAM + mature luminal, CD73 + /EpCAM + /CD90 - rare endogenous pluripotent somatic stem, CD73 + /CD90 + /EpCAM - , estrogen receptor alpha-expressing ALCAM (CD166) + /EpCAM + , and ALDFLUOR + stem/luminal progenitor subpopulations. Epithelial cells were luminal (KRT19 + ), basal (KRT14 + ), or dual-positive luminal/basal hybrid cells. While breast
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.